Drug Trial Radar · NCT06001788
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Last checked: Nov 21, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
171
Planned (sponsor's estimate)
Start
Feb 22, 2024
Primary completion
Dec 2026
Study completion Aug 2027
Sponsor
- Lead sponsor
- Kura Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Conditions
- AML
- AML With Mutated NPM1
- Hematologic Malignancy
- KMT2Ar
- NPM1 Mutation
- MLL Rearrangement
- Leukemia
- Acute Myeloid Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Acute Leukemia
- Neoplasms by Histologic Type
Interventions
ZiftomenibDrug
Oral administration
FludarabineDrug
Intravenous infusion
IdarubicinDrug
Intravenous infusion
CytarabineDrug
Intravenous Infusion
GilteritinibDrug
Oral administration
Granulocyte colony-stimulating factorBiological
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of dose limiting toxicities (DLTs) per dose levelTime frame: During the first 28 days of ziftomenib in combination with SOC treatment (1 cycle)
- Descriptive statistics of adverse eventsTime frame: First dose of ziftomenib up to and including 28 days after last dose of ziftomenib, or if the patient is lost to follow-up, whichever comes first
Locations
45 sites in 3 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCLA Health - Bowyer Oncology Center
Los Angeles, California · Recruiting
UC Irvine Health Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut · Recruiting
Emory Healthcare - The Emory Clinic
Atlanta, Georgia · Recruiting
Georgia Cancer Center at Augusta University
Augusta, Georgia · Recruiting
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois · Recruiting
Loyola University Medical Center
Maywood, Illinois · Recruiting
Simmons Cancer Institute
Springfield, Illinois · Withdrawn
University of Iowa Hospitals & Clinics
Iowa City, Iowa · Recruiting
The University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Henry Ford Cancer Institute
Detroit, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
Northwell Health, LLC PRIME
Lake Success, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Weill Cornell Medical College-NY Presbyterian Hospital
New York, New York · Recruiting
Wilmot Cancer Institute, University of Rochester
Rochester, New York · Recruiting
Stony Brook Cancer Center
Stony Brook, New York · Recruiting
Atrium Health Levine Cancer Center
Charlotte, North Carolina · Recruiting
UH Seidman Cancer Center
Cleveland, Ohio · Recruiting
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Lehigh Valley Topper Cancer Institute
Allentown, Pennsylvania · Withdrawn
Prisma Health
Greenville, South Carolina · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Vermont
Burlington, Vermont · Recruiting
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia · Recruiting
University of Washington
Seattle, Washington · Recruiting
Froedtert & Medical College Clinics
Milwaukee, Wisconsin · Recruiting
IRCCS Azienda Ospedaliero-Universitaria do Bologna - Policlinico di Sant'Orsola
Bologna, Italy · Recruiting
Ospedale Santa Maria delle Croci
Ravenna, Italy · Recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.